Pluristem Therapeutics Inc. the leading biotechnology company in regenerative medicine, announced the commencement of its multinational Phase III multicenter research on muscle regeneration. The study has been conducted to support muscle regeneration associated with notable trauma such as hip fractures. The company is further noticed to develop placenta-based cell therapy products.
PromoCell GmbH to lead research on immunotherapies through all human primary cells and blood & stem cells, including MHC class I genes HLA-A, -B, and -C.
Author Credits: Radhika Gupta, Shivam Bhutani